|
1
|
Gold P and Freedman SO: Demonstration of
tumor-specific antigens in human colonic carcinomata by
immunological tolerance and absorption techniques. J Exp Med.
121:439–462. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Krupey J, Gold P and Freedman SO:
Purification and characterization of carcinoembryonic antigens of
the human digestive system. Nature. 215:67–68. 1967. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wahl RL, Philpott G and Parker CW:
Monoclonal antibody radioimmunodetection of human-derived colon
cancer. Invest Radiol. 18:58–62. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jeon BG, Shin R, Chung JK, Jung IM and Heo
SC: Individualized cutoff value of the preoperative
carcinoembryonic antigen level is necessary for optimal use as a
prognostic marker. Ann Coloproctol. 29:106–114. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang KL, Yang SH, Liang WY, Kuo YJ, Lin
JK, Lin TC, Chen WS, Jiang JK, Wang HS, Chang SC, et al:
Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment
outcome of rectal cancer patients receiving pre-operative
chemoradiation and surgery. Radiat Oncol. 8:432013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Eftekhar E and Naghibalhossaini F:
Carcinoembryonic antigen expression level as a predictive factor
for response to 5-fluorouracil in colorectal cancer. Mol Biol Rep.
41:459–466. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Das A, Barik S, Banerjee S, Bose A, Sarkar
K, Biswas J, Baral R and Pal S: A monoclonal antibody against neem
leaf glycoprotein recognizes carcinoembryonic antigen (CEA) and
restricts CEA expressing tumor growth. J Immunother. 37:394–406.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Conaghan P, Ashraf S, Tytherleigh M,
Wilding J, Tchilian E, Bicknell D, Mortensen NJ and Bodmer W:
Targeted killing of colorectal cancer cell lines by a humanised
IgG1 monoclonal antibody that binds to membrane-bound
carcinoembryonic antigen. Br J Cancer. 98:1217–1225. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Koppe MJ, Bleichrodt RP, Soede AC,
Verhofstad AA, Goldenberg DM, Oyen WJ and Boerman OC:
Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-,
(88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to
carcinoembryonic antigen in mice with small peritoneal metastases
of colorectal origin. J Nucl Med. 45:1224–1232. 2004.PubMed/NCBI
|
|
10
|
Olafsen T and Wu AM: Antibody vectors for
imaging. Semin Nucl Med. 40:167–181. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chakravarty R, Goel S and Cai W: Nanobody:
The ‘magic bullet’ for molecular imaging? Theranostics. 4:386–398.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Siontorou CG: Nanobodies as novel agents
for disease diagnosis and therapy. Int J Nanomedicine. 8:4215–4227.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Desmyter A, Decanniere K, Muyldermans S
and Wyns L: Antigen specificity and high affinity binding provided
by one single loop of a camel single-domain antibody. J Biol Chem.
276:26285–26290. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cancer of the Lung and Bronchus-SEER Stat
Fact Sheets 2016. 2016.
|
|
15
|
Grunnet M and Sorensen JB:
Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung
Cancer. 76:138–143. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tomita M, Shimizu T, Ayabe T, Yonei A and
Onitsuka T: Prognostic significance of tumour marker index based on
preoperative CEA and CYFRA 21-1 in non-small cell lung cancer.
Anticancer Res. 30:3099–3102. 2010.PubMed/NCBI
|
|
17
|
Ghosh I, Bhattacharjee D, Das AK,
Chakrabarti G, Dasgupta A and Dey SK: Diagnostic role of tumour
markers CEA, CA15-3, CA19-9 and CA125 in lung cancer. Indian J Clin
Biochem. 28:24–29. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dai H, Liu J, Liang L, Ban C, Jiang J, Liu
Y, Ye Q and Wang C: Increased lung cancer risk in patients with
interstitial lung disease and elevated CEA and CA125 serum tumour
markers. Respirology. 19:707–713. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu GL, Liu X, Lv XB, Wang XP, Fang XS and
Sang Y: miR-148b functions as a tumor suppressor in non-small cell
lung cancer by targeting carcinoembryonic antigen (CEA). Int J Clin
Exp Med. 7:1990–1999. 2014.PubMed/NCBI
|
|
20
|
Bell A, Wang ZJ, Arbabi-Ghahroudi M, Chang
TA, Durocher Y, Trojahn U, Baardsnes J, Jaramillo ML, Li S, Baral
TN, et al: Differential tumor-targeting abilities of three
single-domain antibody formats. Cancer Lett. 289:81–90. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu W, Li S, Zhang W, Sun J, Ren G and Dong
Q: A novel VHH antibody targeting the B cell-activating factor for
B-cell lymphoma. Int J Mol Sci. 15:9481–9496. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xavier C, Devoogdt N, Hernot S, Vaneycken
I, D'Huyvetter M, De Vos J, Massa S, Lahoutte T and Caveliers V:
Site-specific labeling of his-tagged Nanobodies with
99mTc: A practical guide. Methods Mol Biol. 911:485–490.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gainkam LO, Huang L, Caveliers V, Keyaerts
M, Hernot S, Vaneycken I, Vanhove C, Revets H, De Baetselier P and
Lahoutte T: Comparison of the biodistribution and tumor targeting
of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole
SPECT/micro-CT. J Nucl Med. 49:788–795. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Aerts A, Impens NR, Gijs M, D'Huyvetter M,
Vanmarcke H, Ponsard B, Lahoutte T, Luxen A and Baatout S:
Biological carrier molecules of radiopharmaceuticals for molecular
cancer imaging and targeted cancer therapy. Curr Pharm Des.
20:5218–5244. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Teng FF, Meng X, Sun XD and Yu JM: New
strategy for monitoring targeted therapy: Molecular imaging. Int J
Nanomedicine. 8:3703–3713. 2013.PubMed/NCBI
|
